SUMO2 and hepatocellular carcinoma: also showed that K110 in human Nrf2 is a bona fide SUMO‐acceptor for SUMO‐1 and has a role in serine biosynthesis in hepatocellular carcinoma.[29] Consistent with these reports, we demonstrated that Nrf2 was predominantly modified by SUMO2/3 compared with SUMO1.